Got drug controller nod for Favipiravir’s clinical trial on COVID-19 patients: CSIR DG

By: |
Published: May 9, 2020 9:58 AM

The CSIR has already tied up with Cadila Pharmaceuticals Ltd to evaluate Mycobacterium W (Mw) for faster recovery of hospitalised COVID-19 patients and minimise the spread of disease.

Drug controller of India, CSIR, Favipiravir, Favipiravir clinical trial, coronavirus pandemic, coronavirus in India, coronavirus treatment, coronavirus drug, coronavirus vaccine, coronavirus treatment India, Indian Institute of Chemical Technology, IICTThe technology has been transferred to a private company, IICT Director S Chandrashekar said.

The Drug Controller of India has allowed clinical trial of Favipiravir medicine, developed indigenously a CSIR laboratory, on coronavirus patients, Director General Shekhar Mande said on Friday.

He said the Indian Institute of Chemical Technology (IICT), Hyderabad has developed the technology to make the drug Favipiravir.

Catch live updates on coronavirus here

The technology has been transferred to a private company, IICT Director S Chandrashekar said.

The company will now tie up with hospitals for clinical trials so that the drug could be tested on patients suffering from COVID-19. Approval from patients will be necessary as per the protocols, he said.

Mande said Favipiravir is used in countries such as China and Japan to treat influenza. Whenever, a virus enters a cell, it tries to create multiple replicas. Favipiravir stops the replication process, he explained.

The CSIR has already tied up with Cadila Pharmaceuticals Ltd to evaluate Mycobacterium W (Mw) for faster recovery of hospitalised COVID-19 patients and minimise the spread of disease.

Mycobacterium W can reduce mortality of patients suffering from Gram-negative sepsis by 50 per cent. Permission has been granted by the Drug Controller of India to conduct tests on critically ill COVD-19 patients at three major hospitals in the country, he said.

Mande said Mycobacterium W helps in boosting TH1 and TH2 cells, which in turn, builds immunity in fighting viruses and in this specific case the novel coronavirus.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19: West Bengal reports 54 fresh deaths, 2,936 new cases of coronavirus
2Covid-19: Puducherry CM announces total lockdown on every Tuesday
3Maharashtra: 12,712 new Covid cases, 13,804 recoveries, 344 deaths